SCHEMBL990747

SCHEMBL990747

COC(=O)Cc1cc(Br)cnc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
PDGFRB P09619 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
FLT1 P17948 1/20 0.44
FGFR3 P22607 1/20 0.44
KDR P35968 1/20 0.44
PTGS2 P35354 1/20 0.36
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
HSP90AB1 P08238 1/20 0.34
CYP2C19 P33261 2/20 0.33
KDM4E B2RXH2 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PSMD14 O00487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343731 0.78 HSP90AB1 (0.39) MAPTPDGFRBFGFR1PDGFRAFLT1
SCHEMBL31326134 0.78 HSP90AB1 (0.39) MAPTPDGFRBFGFR1PDGFRAFLT1
SCHEMBL27658355 0.78 KMT2A (0.37) MAPTPOLBHTTLMNAKMT2A
SCHEMBL2122851 0.78 PDGFRB (0.44) MAPTPOLBHTTPDGFRBFGFR1
SCHEMBL18512305 0.77 TSHR (0.38) MAPTPDGFRBFGFR1PDGFRAFLT1
SCHEMBL21326695 0.77 HSP90AB1 (0.38) MAPTPDGFRBFGFR1PDGFRAFLT1
SCHEMBL12681547 0.77 HTT (0.42) POLBHTTHSP90AB1KDM4EMEN1
SCHEMBL990666 0.75 SIRT6 (0.46) MAPTPOLBPDGFRBFGFR1PDGFRA
SCHEMBL21963842 0.75 MAPT (0.38) MAPTPOLBHTTLMNAPKM
SCHEMBL24923428 0.75 MAPT (0.38) MAPTPOLBHTTLMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745037-B1 Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases NOVARTIS AG (CH) 2013-01-02 EP disclosed
EP-2270001-A1 Indolylmaleimide derivatives as PKC inhibitors Novartis AG (CH) 2011-01-05 EP disclosed
US-7648989-B2 Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG (CH) 2010-01-19 US disclosed
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors NOVARTIS AG (CH) 2008-10-02 US disclosed
EP-1745037-A1 INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS Novartis AG (CH) 2007-01-24 EP disclosed
WO-2005068455-A1 INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS NOVARTIS AG (CH) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors PRKCE, PRKCH, PRKCI MAPT 3424/4885POLB 4423/4885HTT 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.